Prognosis method of cancer

A method of prognosis of the outcome of a patient afflicted by a tumor, said method comprising the following steps:

• determining, in a sample of said tumor, the amount of the product of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160,
• said 21 genes being the genes of the group consisting of the genes as set forth in SEQ ID NO:
• 7, SEQ ID NO:
• 11, SEQ ID NO:
• 14, SEQ ID NO:
• 15, SEQ ID NO:
• 20, SEQ ID NO:
• 22, SEQ ID NO:
• 28, SEQ ID NO:
• 30, SEQ ID NO:
• 34, SEQ ID NO:
• 40, SEQ ID NO:
• 54, SEQ ID NO:
• 72, SEQ ID NO:
• 74, SEQ ID NO:
• 76, SEQ ID NO:
• 100, SEQ ID NO:
• 102, SEQ ID NO:
• 127, SEQ ID NO:
• 141, SEQ ID NO:
• 149, SEQ ID NO:
• 150 and SEQ ID NO:
• 160,
• comparing said amount of the product of each of at least 21 genes determined in the previous step with the reference amount of each gene of the corresponding at least 21 genes from the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160, said reference amount being obtained from a biological sample different from said tumor, and
• establishing a poor patient outcome when the ratio between the said amount and said reference amount is higher than or equal to 1.2, for each gene of said at least 21 genes.

A method of prediction of the resistance to a chemotherapy treatment of an individual afflicted by a tumor, said chemotherapy treatment being one of the following treatment:

• a treatment with Nutlin-3a, with 17-AAG, with AZD8055, with Temsirolimus, with EHT 1864, with PF-4708671 or with ATRA, said method comprising:
• determining, in a sample of said tumor, the amount of the product of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160, said 21 genes being the genes of the group consisting of the genes as set forth in SEQ ID NO:
• 7, SEQ ID NO:
• 11, SEQ ID NO:
• 14, SEQ ID NO:
• 15, SEQ ID NO:
• 20, SEQ ID NO:
• 22, SEQ ID NO:
• 28, SEQ ID NO:
• 30, SEQ ID NO:
• 34, SEQ ID NO:
• 40, SEQ ID NO:
• 54, SEQ ID NO:
• 72, SEQ ID NO:
• 74, SEQ ID NO:
• 76, SEQ ID NO:
• 100, SEQ ID NO:
• 102, SEQ ID NO:
• 127, SEQ ID NO:
• 141, SEQ ID NO:
• 149, SEQ ID NO:
• 150 and SEQ ID NO:
• 160,
• comparing said amount of the product of each of at least 21 genes determined in the previous step with the reference amount of each gene of the corresponding at least 21 genes from the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160, said reference amount being obtained from a biological sample different from said tumor, and
• establishing the resistance to a chemotherapy of said biological sample, when the ratio between the said amount and said reference amount is higher than or equal to 1.2, for each gene of said at least 21 genes.

A method of prediction of the sensitivity to a chemotherapy treatment of an individual afflicted by a tumor, said chemotherapy treatment being one of the following treatment:

• a taxane-anthracycline chemotherapy, a treatment with PF-023410066, with AZD7762, with DMOG, with Thapsigarpin, with CHIR-99021, with AZD6244, with JNJ26854165, with JNK-9L or with PF563371, said method comprising:
• determining, in a sample of said tumor, the amount of the product of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160,
• Said 21 genes being the genes of the group consisting of the genes as set forth in SEQ ID NO:
• 7, SEQ ID NO:
• 11, SEQ ID NO:
• 14, SEQ ID NO:
• 15, SEQ ID NO:
• 20, SEQ ID NO:
• 22, SEQ ID NO:
• 28, SEQ ID NO:
• 30, SEQ ID NO:
• 34, SEQ ID NO:
• 40, SEQ ID NO:
• 54, SEQ ID NO:
• 72, SEQ ID NO:
• 74, SEQ ID NO:
• 76, SEQ ID NO:
• 100, SEQ ID NO:
• 102, SEQ ID NO:
• 127, SEQ ID NO:
• 141, SEQ ID NO:
• 149, SEQ ID NO:
• 150 and SEQ ID NO:
• 160,
• comparing said amount of the product of each of at least 21 genes determined in the previous step with the reference amount of each gene of the corresponding at least 21 genes from the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160, said reference amount being obtained from a biological sample different from said tumor, and
• establishing the sensitivity to a chemotherapy of said biological sample, when the ratio between the said amount and said reference amount is higher than or equal to 1.2, for each gene of said at least 21 genes

A method for evaluating in vitro the efficiency of an anticancer drug, said method comprising the steps of:

• a) determining, in a biological sample of a tumor previously treated with said anticancer drug, the amount of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160, Said 21 genes being the genes of the group consisting of the genes as set forth in SEQ ID NO:
• 7, SEQ ID NO:
• 11, SEQ ID NO:
• 14, SEQ ID NO:
• 15, SEQ ID NO:
• 20, SEQ ID NO:
• 22, SEQ ID NO:
• 28, SEQ ID NO:
• 30, SEQ ID NO:
• 34, SEQ ID NO:
• 40, SEQ ID NO:
• 54, SEQ ID NO:
• 72, SEQ ID NO:
• 74, SEQ ID NO:
• 76, SEQ ID NO:
• 100, SEQ ID NO:
• 102, SEQ ID NO:
• 127, SEQ ID NO:
• 141, SEQ ID NO:
• 149, SEQ ID NO:
• 150 and SEQ ID NO:
• 160,
• b) comparing said the amount of the product of each of at least 21 genes determined in the previous step with the reference amount of each gene of the corresponding at least 21 genes from the group of 160 genes as set forth in SEQ ID NO:
• 1 to SEQ ID NO:
• 160, said reference amount being obtained from a biological sample different from said tumor,
• c) establishing the efficiency of anticancer drug, when the ratio between the said amount and said reference amount, for each gene of said at least 21 genes is lower than or equal to 1.2.